Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

JAMA Surg. 2018 May 16:e180996. doi: 10.1001/jamasurg.2018.0996. [Epub ahead of print]

PMID:
29799910
2.

Leukocyte telomere length throughout the continuum of colorectal carcinogenesis.

Zöchmeister C, Brezina S, Hofer P, Baierl A, Bergmann MM, Bachleitner-Hofmann T, Karner-Hanusch J, Stift A, Gerger A, Leeb G, Mach K, Rachakonda S, Kumar R, Gsur A.

Oncotarget. 2018 Feb 7;9(17):13582-13592. doi: 10.18632/oncotarget.24431. eCollection 2018 Mar 2.

3.

Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer.

Posch F, Silina K, Leibl S, Mündlein A, Moch H, Siebenhüner A, Samaras P, Riedl J, Stotz M, Szkandera J, Stöger H, Pichler M, Stupp R, van den Broek M, Schraml P, Gerger A, Petrausch U, Winder T.

Oncoimmunology. 2017 Dec 18;7(2):e1378844. doi: 10.1080/2162402X.2017.1378844. eCollection 2018.

4.

Risk stratification for febrile neutropenia in patients with testicular germ cell tumors.

Terbuch A, Posch F, Partl R, Zurl B, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Kapp KS, Stöger H, Gerger A, Stotz M.

Cancer Med. 2018 Feb;7(2):508-514. doi: 10.1002/cam4.1317. Epub 2018 Jan 19.

5.

Bayesian and frequentist analysis of an Austrian genome-wide association study of colorectal cancer and advanced adenomas.

Hofer P, Hagmann M, Brezina S, Dolejsi E, Mach K, Leeb G, Baierl A, Buch S, Sutterlüty-Fall H, Karner-Hanusch J, Bergmann MM, Bachleitner-Hofmann T, Stift A, Gerger A, Rötzer K, Karner J, Stättner S, Waldenberger M, Meitinger T, Strauch K, Linseisen J, Gieger C, Frommlet F, Gsur A.

Oncotarget. 2017 Oct 9;8(58):98623-98634. doi: 10.18632/oncotarget.21697. eCollection 2017 Nov 17.

6.

Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting.

Riedl JM, Posch F, Moik F, Bezan A, Szkandera J, Smolle MA, Kasparek AK, Pichler M, Stöger H, Stotz M, Gerger A.

Oncotarget. 2017 Oct 4;8(56):96048-96061. doi: 10.18632/oncotarget.21647. eCollection 2017 Nov 10.

7.

SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types.

Richtig G, Aigelsreiter A, Schwarzenbacher D, Ress AL, Adiprasito JB, Stiegelbauer V, Hoefler G, Schauer S, Kiesslich T, Kornprat P, Winder T, Eisner F, Gerger A, Stoeger H, Stauber R, Lackner C, Pichler M.

PLoS One. 2017 Nov 9;12(11):e0187814. doi: 10.1371/journal.pone.0187814. eCollection 2017.

8.

Benefit of Adjuvant Radiotherapy for Local Control, Distant Metastasis, and Survival Outcomes in Patients with Localized Soft Tissue Sarcoma: Comparative Effectiveness Analysis of an Observational Cohort Study.

Posch F, Partl R, Döller C, Riedl JM, Smolle M, Leitner L, Bergovec M, Liegl-Atzwanger B, Stotz M, Bezan A, Gerger A, Pichler M, Kapp KS, Stöger H, Leithner A, Szkandera J.

Ann Surg Oncol. 2018 Mar;25(3):776-783. doi: 10.1245/s10434-017-6080-3. Epub 2017 Sep 11.

9.

Long-term cardiovascular complications in stage I seminoma patients.

Terbuch A, Posch F, Annerer LM, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Partl R, Kapp KS, Stöger H, Gerger A, Stotz M.

Clin Transl Oncol. 2017 Nov;19(11):1400-1408. doi: 10.1007/s12094-017-1742-y. Epub 2017 Aug 29.

10.

MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.

Goblirsch M, Richtig G, Slaby O, Berindan-Neagoe I, Gerger A, Pichler M.

Pharmacogenomics. 2017 Jul;18(10):1027-1038. doi: 10.2217/pgs-2017-0004. Epub 2017 Jun 22. Review.

PMID:
28639472
11.

Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.

Riedl JM, Posch F, Bezan A, Szkandera J, Smolle MA, Winder T, Rossmann CH, Schaberl-Moser R, Pichler M, Stotz M, Stöger H, Gerger A.

BMC Cancer. 2017 Jun 15;17(1):415. doi: 10.1186/s12885-017-3392-4.

12.

miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.

Stiegelbauer V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, Reicher A, Resel M, Heitzer E, Ivan C, Bullock M, Ling H, Deutsch A, Wulf-Goldenberg A, Adiprasito JB, Stoeger H, Haybaeck J, Svoboda M, Stotz M, Hoefler G, Slaby O, Calin GA, Gerger A, Pichler M.

Clin Cancer Res. 2017 Sep 1;23(17):5255-5266. doi: 10.1158/1078-0432.CCR-17-0023. Epub 2017 May 22.

PMID:
28533224
13.

Future perspectives of circulating tumor DNA in colorectal cancer.

Nadal C, Winder T, Gerger A, Tougeron D.

Tumour Biol. 2017 May;39(5):1010428317705749. doi: 10.1177/1010428317705749.

PMID:
28488528
14.

Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.

Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyer J, Winder T, Hermanns T, Fankhauser CD, Gerger A, Stotz M.

PLoS One. 2017 Apr 21;12(4):e0176283. doi: 10.1371/journal.pone.0176283. eCollection 2017.

15.

Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.

Stotz M, Herzog SA, Pichler M, Smolle M, Riedl J, Rossmann C, Bezan A, Stöger H, Renner W, Berghold A, Gerger A.

Anticancer Res. 2017 Apr;37(4):2011-2018.

PMID:
28373475
16.

My personal highlights of ESMO 2016.

Dediu M, Gerger A, Zojer N, Bartsch R.

Memo. 2017;10(1):46-47. doi: 10.1007/s12254-017-0314-8. Epub 2017 Feb 8.

17.

Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?

Posch F, Leitner L, Bergovec M, Bezan A, Stotz M, Gerger A, Pichler M, Stöger H, Liegl-Atzwanger B, Leithner A, Szkandera J.

Clin Orthop Relat Res. 2017 May;475(5):1427-1435. doi: 10.1007/s11999-017-5232-x. Epub 2017 Jan 12.

18.

Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.

Pehserl AM, Ress AL, Stanzer S, Resel M, Karbiener M, Stadelmeyer E, Stiegelbauer V, Gerger A, Mayr C, Scheideler M, Hutterer GC, Bauernhofer T, Kiesslich T, Pichler M.

Int J Mol Sci. 2016 Dec 1;17(12). pii: E2011.

19.

Serum sclerostin levels in renal cell carcinoma patients with bone metastases.

Wibmer C, Amrein K, Fahrleitner-Pammer A, Gilg MM, Berghold A, Hutterer GC, Maurer-Ertl W, Gerger A, Leithner A, Pichler M, Szkandera J.

Sci Rep. 2016 Sep 26;6:33551. doi: 10.1038/srep33551.

20.

Current Status of Long Non-Coding RNAs in Human Breast Cancer.

Cerk S, Schwarzenbacher D, Adiprasito JB, Stotz M, Hutterer GC, Gerger A, Ling H, Calin GA, Pichler M.

Int J Mol Sci. 2016 Sep 6;17(9). pii: E1485. doi: 10.3390/ijms17091485. Review.

21.

Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.

Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X, Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, Haybaeck J, Svoboda M, Okugawa Y, Gerger A, Hoefler G, Goel A, Slaby O, Calin GA.

Clin Cancer Res. 2017 Mar 1;23(5):1323-1333. doi: 10.1158/1078-0432.CCR-16-0497. Epub 2016 Sep 6.

22.

Blood-Based Biomarkers Are Associated with Disease Recurrence and Survival in Gastrointestinal Stroma Tumor Patients after Surgical Resection.

Stotz M, Liegl-Atzwanger B, Posch F, Mrsic E, Thalhammer M, Stojakovic T, Bezan A, Pichler M, Gerger A, Szkandera J.

PLoS One. 2016 Jul 25;11(7):e0159448. doi: 10.1371/journal.pone.0159448. eCollection 2016.

23.

The AST/ALT (De-Ritis) ratio: A novel marker for critical limb ischemia in peripheral arterial occlusive disease patients.

Rief P, Pichler M, Raggam R, Hafner F, Gerger A, Eller P, Brodmann M, Gary T.

Medicine (Baltimore). 2016 Jun;95(24):e3843. doi: 10.1097/MD.0000000000003843.

24.

The width of resection margins influences local recurrence in soft tissue sarcoma patients.

Kainhofer V, Smolle MA, Szkandera J, Liegl-Atzwanger B, Maurer-Ertl W, Gerger A, Riedl J, Leithner A.

Eur J Surg Oncol. 2016 Jun;42(6):899-906. doi: 10.1016/j.ejso.2016.03.026. Epub 2016 Apr 12.

PMID:
27107792
25.

Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma.

Seles M, Hutterer GC, Kiesslich T, Pummer K, Berindan-Neagoe I, Perakis S, Schwarzenbacher D, Stotz M, Gerger A, Pichler M.

Int J Mol Sci. 2016 Apr 15;17(4):573. doi: 10.3390/ijms17040573. Review.

26.

Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.

Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD, Pichler M.

Anticancer Res. 2015 Nov;35(11):5737-44. Review.

PMID:
26503994
27.

An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients.

Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Breast. 2015 Oct;24(5):667-72. doi: 10.1016/j.breast.2015.08.003. Epub 2015 Sep 4.

PMID:
26346586
28.

Genetic markers of recurrence in colorectal cancer.

Smolle MA, Pichler M, Haybaeck J, Gerger A.

Pharmacogenomics. 2015;16(11):1315-28. doi: 10.2217/pgs.15.83. Epub 2015 Aug 12. Review.

PMID:
26266878
29.

The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients.

Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Tumour Biol. 2016 Jan;37(1):361-8. doi: 10.1007/s13277-015-3805-4. Epub 2015 Jul 29.

PMID:
26219894
30.

Vitamin D and prostate cancer prognosis: a Mendelian randomization study.

Trummer O, Langsenlehner U, Krenn-Pilko S, Pieber TR, Obermayer-Pietsch B, Gerger A, Renner W, Langsenlehner T.

World J Urol. 2016 Apr;34(4):607-11. doi: 10.1007/s00345-015-1646-9. Epub 2015 Jul 25.

PMID:
26209090
31.

Low spinophilin expression enhances aggressive biological behavior of breast cancer.

Schwarzenbacher D, Stiegelbauer V, Deutsch A, Ress AL, Aigelsreiter A, Schauer S, Wagner K, Langsenlehner T, Resel M, Gerger A, Ling H, Ivan C, Calin GA, Hoefler G, Rinner B, Pichler M.

Oncotarget. 2015 May 10;6(13):11191-202.

32.

Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy.

Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger A, Langsenlehner U.

Urol Oncol. 2015 May;33(5):201.e9-16. doi: 10.1016/j.urolonc.2015.02.002. Epub 2015 Mar 11.

PMID:
25769845
33.

Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.

Reitz D, Gerger A, Seidel J, Kornprat P, Samonigg H, Stotz M, Szkandera J, Pichler M.

J Clin Pathol. 2015 Jun;68(6):427-33. doi: 10.1136/jclinpath-2014-202451. Epub 2015 Mar 10. Erratum in: J Clin Pathol. 2015 Jul;68(7):e2.

PMID:
25759406
34.

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.

Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberl-Moser R, Samonigg H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger A.

Pharmacogenomics J. 2015 Oct;15(5):391-6. doi: 10.1038/tpj.2015.2. Epub 2015 Feb 10.

35.

The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Eur J Cancer. 2015 Mar;51(5):610-9. doi: 10.1016/j.ejca.2015.01.002. Epub 2015 Jan 21.

PMID:
25618827
36.

Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.

Langsenlehner T, Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Gerger A, Pichler M.

World J Urol. 2015 Nov;33(11):1661-7. doi: 10.1007/s00345-015-1494-7. Epub 2015 Jan 24.

PMID:
25617235
37.

The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Friesenbichler J, Stojakovic T, Leithner A, Pichler M.

Am J Surg. 2015 Jul;210(1):111-6. doi: 10.1016/j.amjsurg.2014.10.021. Epub 2014 Dec 18.

PMID:
25586599
38.

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.

Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):226-34. doi: 10.1038/tpj.2014.66. Epub 2014 Dec 9.

PMID:
25487679
39.

The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

World J Urol. 2015 Oct;33(10):1467-73. doi: 10.1007/s00345-014-1459-2. Epub 2014 Dec 5.

PMID:
25475065
40.

The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer.

Stotz M, Szkandera J, Stojakovic T, Seidel J, Samonigg H, Kornprat P, Schaberl-Moser R, Seggewies F, Hoefler G, Gerger A, Pichler M.

Clin Chem Lab Med. 2015 Feb;53(3):499-506. doi: 10.1515/cclm-2014-0447.

PMID:
25389993
41.

Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer.

Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ.

Pharmacogenet Genomics. 2015 Jan;25(1):30-7. doi: 10.1097/FPC.0000000000000101.

42.

Lymphocyte-to-monocyte ratio: a novel marker for critical limb ischemia in PAOD patients.

Gary T, Pichler M, Belaj K, Eller P, Hafner F, Gerger A, Brodmann M.

Int J Clin Pract. 2014 Dec;68(12):1483-7. doi: 10.1111/ijcp.12495. Epub 2014 Oct 31.

PMID:
25359092
43.

Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Ploner F, Stojakovic T, Gary T, Leithner A, Pichler M.

Clin Chem Lab Med. 2015 Feb;53(3):493-7. doi: 10.1515/cclm-2014-0486.

PMID:
25324451
44.

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X.

Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfler A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H.

Nat Commun. 2014 Oct 13;5:5191. doi: 10.1038/ncomms6191.

45.

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):235-40. doi: 10.1038/tpj.2014.58. Epub 2014 Oct 7.

PMID:
25287073
46.

Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.

Ress AL, Stiegelbauer V, Schwarzenbacher D, Deutsch A, Perakis S, Ling H, Ivan C, Calin GA, Rinner B, Gerger A, Pichler M.

Oncotarget. 2014 Sep 30;5(18):8492-502.

47.

MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients.

Ress AL, Stiegelbauer V, Winter E, Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A, Bauernhofer T, Ling H, Samonigg H, Gerger A, Hoefler G, Pichler M.

Mol Carcinog. 2015 Nov;54(11):1442-50. doi: 10.1002/mc.22218. Epub 2014 Sep 25.

PMID:
25256312
48.

Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Ploner F, Stojakovic T, Leithner A, Pichler M.

PLoS One. 2014 Sep 10;9(9):e107297. doi: 10.1371/journal.pone.0107297. eCollection 2014.

49.

MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.

Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M.

World J Gastroenterol. 2014 Sep 7;20(33):11727-35. doi: 10.3748/wjg.v20.i33.11727. Review.

50.

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ.

Pharmacogenet Genomics. 2014 Dec;24(12):588-96. doi: 10.1097/FPC.0000000000000091.

Supplemental Content

Loading ...
Support Center